Gilead Sciences, Inc. (NASDAQ:GILD) EVP Gregg H. Alton sold 25,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $82.65, for a total transaction of $2,066,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Gilead Sciences, Inc. (NASDAQ GILD) opened at 82.14 on Friday. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The company has a market cap of $107.27 billion, a PE ratio of 8.92 and a beta of 1.14. The firm’s 50-day moving average is $80.97 and its 200-day moving average is $71.66.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. During the same quarter in the previous year, the firm earned $3.08 EPS. The company’s quarterly revenue was down 8.2% compared to the same quarter last year. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post $8.75 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were issued a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.53%. Gilead Sciences’s dividend payout ratio is presently 22.58%.

WARNING: “Gilead Sciences, Inc. (GILD) EVP Sells $2,066,250.00 in Stock” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/gilead-sciences-inc-gild-evp-sells-2066250-00-in-stock/1614369.html.

A number of analysts have recently commented on the stock. Jefferies Group LLC reiterated a “hold” rating and issued a $80.00 price target on shares of Gilead Sciences in a research note on Tuesday, July 11th. Morgan Stanley reiterated an “equal weight” rating and issued a $83.00 price target (up from $77.00) on shares of Gilead Sciences in a research note on Friday. BMO Capital Markets reiterated an “outperform” rating and issued a $82.00 price target (up from $72.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Robert W. Baird reiterated an “outperform” rating and issued a $87.00 price target on shares of Gilead Sciences in a research note on Thursday, July 13th. Finally, J P Morgan Chase & Co restated an “overweight” rating and set a $82.00 target price on shares of Gilead Sciences in a research report on Tuesday, July 4th. Twelve analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $85.66.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Waldron LP increased its position in shares of Gilead Sciences by 20.4% during the 1st quarter. Waldron LP now owns 10,360 shares of the biopharmaceutical company’s stock worth $711,000 after purchasing an additional 1,752 shares during the last quarter. Robshaw & Julian Associates Inc. increased its position in shares of Gilead Sciences by 22.5% during the 1st quarter. Robshaw & Julian Associates Inc. now owns 43,510 shares of the biopharmaceutical company’s stock worth $2,955,000 after purchasing an additional 8,000 shares during the last quarter. NBT Bank N A NY increased its position in shares of Gilead Sciences by 203.8% during the 1st quarter. NBT Bank N A NY now owns 41,272 shares of the biopharmaceutical company’s stock worth $2,804,000 after purchasing an additional 27,685 shares during the last quarter. Mycio Wealth Partners LLC increased its position in shares of Gilead Sciences by 13.0% during the 1st quarter. Mycio Wealth Partners LLC now owns 10,146 shares of the biopharmaceutical company’s stock worth $689,000 after purchasing an additional 1,165 shares during the last quarter. Finally, Cubic Asset Management LLC increased its position in shares of Gilead Sciences by 1.9% during the 1st quarter. Cubic Asset Management LLC now owns 29,701 shares of the biopharmaceutical company’s stock worth $2,017,000 after purchasing an additional 560 shares during the last quarter. Institutional investors and hedge funds own 73.99% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.